Copyright
©The Author(s) 2016.
World J Diabetes. Nov 15, 2016; 7(19): 534-546
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534
Figure 13 Immunohistochemical staining for lymphatic vessel endothelial hyaluronan receptor-1 in the liver of intact (A and B), placebo-treated (C) and linagliptin-treated (D, E and F) db/db mice.
Staining by anti-LYVE-1 antibodies, indirect streptavidin-biotin method; A, C, E and F: × 400; B and D: × 100. LYVE-1: Lymphatic vessel endothelial hyaluronan receptor-1.
- Citation: Michurina SV, Ishenko IJ, Klimontov VV, Archipov SA, Myakina NE, Cherepanova MA, Zavjalov EL, Koncevaya GV, Konenkov VI. Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J Diabetes 2016; 7(19): 534-546
- URL: https://www.wjgnet.com/1948-9358/full/v7/i19/534.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i19.534